Development, evaluation, and application of an In Silico model for antimalarial drug treatment and failure

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3380-3392

  Winter, Katherine ^a   Hastings, Ian M ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; MEFLOQUINE; PIPERAQUINE;

ANTIMALARIAL THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG THERAPY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FOLLOW UP; IC 50; MALARIA; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIMALARIALS; ARTEMISININS; HUMANS; MALARIA; MODELS, THEORETICAL;

EID: 79959189146     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01712-10     Document Type: Article

References (76)

1. Adjuik, M., et al. 2004. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363:9-17.
2. Anderson, T. J. C., et al. 2005. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob. Agents Chemother. 49:2180-2188. (Pubitemid 40734444)
3. Austin, D., N. White, and R. Anderson. 1998. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J. Theor. Biol. 194:313-339.
4. Barnes, K., W. Watkins, and N. White. 2008. Antimalarial dosing regimens and drug resistance. Trends Parasitol. 24:127-134.
5. Brockman, A., et al. 2000. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans. R. Soc. Trop. Med. Hyg. 94:537-544.
6. Burki, T. 2009. Artemisinin resistance could endanger fight against malaria. Lancet 9:213.
7. Campbell, C. C. 2009. Malaria control - addressing challenges to ambitious goals. N. Engl. J. Med. 361:522-523.
8. Checchi, F., et al. 2006. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar. J. 5:59.
9. Chinh, N., et al. 2009. Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob. Agents Chemother. 53:828-831.
10. Chou, T. C. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58:621-681.
11. Colussi, D., C. Parisot, F. Legay, and G. Lefèvre. 1999. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur. J. Pharm. Sci. 9:9-16.
12. Czock, D., and F. Keller. 2007. Mechanism-based pharmacokinetic- pharmacodynamic modeling of antimicrobial drug effects. J. Pharmacokinet. Pharmacodyn. 34:727-751.
13. Daily, J. P. 2006. Antimalarial drug therapy: the role of parasite biology and drug resistance. J. Clin. Pharmacol. 46:1487-1497.
14. Dondorp, A. M., et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
15. Dondorp, A. M., et al. 2010. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 8:272-280.
16. Ducharme, J., and R. Farinotti. 1996. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin. Pharmacokinet. 31:257-274.
17. Enserink, M. 2010. Malaria's drug miracle in danger. Science 328:844-846.
18. Ezzet, F., M. V. Vugt, F. Nosten, S. Looareesuwan, and N. J. White. 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44:697-704.
19. Faye, B., et al. 2010. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am. J. Trop. Med. Hyg. 82:140-144.
20. Gatton, M. L., L. B. Martin, and Q. Cheng. 2004. Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrob. Agents Chemother. 48:2116-2123.
21. Giao, P., and P. de Vries. 2001. Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacokinet. 40:343-373.
22. Goldin, A., and N. Mantel. 1957. The employment of combinations of drugs in the chemotherapy of neoplasia. Cancer Res. 17:635-654.
23. Grande, T., et al. 2007. A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One 2:e1101.
24. Greco, W. R., H. S. Park, and Y. M. Rustum. 1990. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 50:5318-5327.
25. Greenhouse, B., C. Dokomajilar, A. Hubbard, P. J. Rosenthal, and G. Dorsey. 2007. Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob. Agents Chemother. 51:3096-3103.
26. Hastings, I. M., and S. A. Ward. 2005. Coartem (artemether-lumefantrine) in Africa: the beginning of the end? J. Infect. Dis. 192:1303-1304.
27. Hellgren, U., et al. 1991. Chloroquine resistant Plasmodium falciparum malaria in Guinea-Bissau. Trans. R. Soc. Trop. Med. Hyg. 85:1-36.
28. Hombhanje, F., et al. 2004. The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br. J. Clin. Pharmacol. 59:298-301.
29. Hoshen, M., K. Na-Bangchang, W. Stein, and H. Ginsburg. 2000. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy,' a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 121:237-246.
30. Hoshen, M., W. Stein, and H. Ginsburg. 1998. Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Parasitology 116:407-416. (Pubitemid 28221660)
31. Hoshen, M. B., W. D. Stein, and H. D. Ginsburg. 2001. Pharmacokinetic-pharmacodynamic modelling of the anti-malarial activity of mefloquine. Parasitology 123:337-346.
32. Hung, T., et al. 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57:253-262.
33. Kamya, M., A. Yeka, and H. Bukirwa. 2007. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin. Trials 2:1-9.
34. Karunajeewa, H. A., et al. 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359:2545-2557.
35. Kofoed, P., F. Lopez, and P. Johansson. 2002. Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau. Am. J. Trop. Med. Hyg. 67:28-31.
36. Krishna, S., and N. White. 1996. Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clin. Pharmacokinet. 30:263-299.
37. Kyle, D., and H. K. Webster. 1996. Post-antibiotic effect of quinine and dihydroartemisinin on Plasmodium falciparum in vitro: implication for a mechanism of recrudescence, abstr. O-22-6. Abstr. XIV Int. Cong. Trop. Med. Malar.
38. Mayxay, M., et al. 2007. In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos). Am. J. Trop. Med. Hyg. 76:245-250.
39. Mcgready, R., et al. 2006. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62:1021-1031.
40. Mu, J., et al. 2010. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat. Genet. 42:268-271.
41. Nambozi, M., et al. 2011. Safety and efficacy of dihydroartemisinin- piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar. J. 10:50.
42. Nguyen, D. V. H., et al. 2009. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob. Agents Chemother. 53:3534-3537.
43. Nguyen, M. H., et al. 2003. Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine-pyrimethamine be reintroduced in combination with artesunate? Clin. Infect. Dis. 37:1461-1466.
44. Noedl, H., et al. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
45. Painter, H. J., J. M. Morrisey, and A. B. Vaidya. 2010. Mitochondrial electron transport inhibition and viability of intraerythrocytic Plasmodium falciparum. Antimicrob. Agents Chemother. 54:5281-5287.
46. Pongtavornpinyo, W., et al. 2008. Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies. Malar. J. 7:229.
47. Pussard, E., and F. Verdier. 1994. Antimalarial 4-aminoquinolines: mode of action and pharmacokinetics. Fundam. Clin. Pharmacol. 8:1-17.
48. R Development Core Team. 2009. R: a language and environment for statistical computing. R Development Core Team, Vienna, Austria.
49. Sagara, I., et al. 2008. A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am. J. Trop. Med. Hyg. 79:655-661.
50. Sama, W., S. Owusu-Agyei, I. Felger, P. Vounatsou, and T. Smith. 2005. An immigration-death model to estimate the duration of malaria infection when detectability of the parasite is imperfect. Stat. Med. 24:3269-3288.
51. Schneider, P., B. H. K. Chan, S. E. Reece, and A. F. Read. 2008. Does the drug sensitivity of malaria parasites depend on their virulence? Malar. J. 7:257.
52. Schoepflin, S., et al. 2010. Treatment with Coartem (artemether- lumefantrine) in Papua New Guinea. Am. J. Trop. Med. Hyg. 82:529-534.
53. Shen, L., et al. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766.
54. Simpson, J., et al. 2006. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med. 3:2113-2123. (Pubitemid 44875944)
55. Simpson, J., et al. 2000. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother. 44:3414-3424.
56. Sisowath, C., et al. 2007. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop. Med. Int. Health 12:736-742.
57. Sisowath, C., et al. 2009. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Infect. Dis. 199:750-757.
58. Sisowath, C., et al. 2005. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J. Infect. Dis. 191:1014-1017.
59. Stepniewska, K., and N. J. White. 2008. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52:1589-1596.
60. Tarning, J., et al. 2008. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J. Pharm. Sci. 97:3400-3410.
61. Taylor, W., et al. 2006. Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull. World Health Organ. 84:956-964.
62. Teuscher, F., et al. 2010. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J. Infect. Dis. 202:1362-1368.
63. Ursing, J., P. E. Kofoed, A. Rodrigues, Y. Bergqvist, and L. Rombo. 2008. Chloroquine is grossly overdosed and overused but well tolerated in Guinea-Bissau. Antimicrob. Agents Chemother. 53:180-185.
64. Valecha, N., et al. 2009. Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India. Malar. J. 8:107.
65. Ward, S., E. Sevene, I. Hastings, and F. Nosten. 2007. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect. Dis. 7:136-144.
66. White, N. 1999. Antimalarial drug resistance and combination chemotherapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:739-749.
67. White, N. 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41:1413-1422.
68. White, N., P. Chanthavanich, S. Krishna, C. Bunch, and K. Silamut. 1983. Quinine disposition kinetics. Br. J. Clin. Pharmacol. 16:399-403.
69. Reference deleted.
70. White, N. J. 1992. Antimalarial pharmacokinetics and treatment regimens. Br. J. Clin. Pharmacol. 34:1-10.
71. White, N. J., K. Stepniewska, K. Barnes, R. N. Price, and J. Simpson. 2008. Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol. 24:159-163.
72. Wongsrichanalai, C., and S. R. Meshnick. 2008. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg. Infect. Dis. 14:716-719.
73. World Health Organization. 2006. Guidelines for the treatment of malaria. World Health Organization, Geneva, Switzerland.
74. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland.
75. World Health Organization. 2007. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. World Health Organization, Geneva, Switzerland.
76. Yu, V. L., T. C. Merigan, and S. L. Barriere. 2002. Antimicrobial therapy and vaccines, vol. II. Antimicrobial agents. Apple Tree Productions, New York, NY.